HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Fanconi anemia complementation group E: clinical and cytogenetic data of the first patient.

Abstract
The clinical and cytogenetic data of the first patient proven to belong to the fifth Fanconi anemia complementation group are described. The Turkish boy presented with psychomotoric retardation, growth retardation, retarded bone age, brachycephaly, hypotelorism, epicanthus, syndactyly, brachydactyly, renal dystopia, and cryptorchism. In addition, an asymmetrical skeletal anomaly was seen with a double distal phalanx of the left thumb and hypoplasia of the right thumb. Typical hematological features of the disorder developed, at the age of 2.5 years, about 1 year after diagnosis. Cytogenetic studies confirmed the clinical diagnosis and revealed a spontaneous chromosomal instability and hypersensitivity to the cross-linking agents diepoxybutane and Trenimon. The findings in the patient, who is considered to be the standard for the fifth Fanconi anemia complementation group, are compared with data reported for other patients affected with Fanconi anemia.
AuthorsR D Wegner, I Henrichs, H Joenje, T Schroeder-Kurth
JournalClinical genetics (Clin Genet) Vol. 50 Issue 6 Pg. 479-82 (Dec 1996) ISSN: 0009-9163 [Print] Denmark
PMID9147877 (Publication Type: Case Reports, Journal Article)
Topics
  • Cell Line, Transformed
  • Chromosomes, Human (drug effects, ultrastructure)
  • Consanguinity
  • Fanconi Anemia (blood, classification, ethnology, genetics, pathology)
  • Fatal Outcome
  • Fingers (abnormalities)
  • Genetic Complementation Test
  • Humans
  • Infant, Newborn
  • Lymphocytes (ultrastructure)
  • Male
  • Phenotype
  • Turkey (ethnology)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: